Synopsys
SNPS
$401.85
+4.38%
Synopsys Inc. is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP), serving the global semiconductor and electronics industry with tools that automate and optimize chip design from concept to manufacturing. The company occupies a critical, entrenched position in the semiconductor supply chain, functioning as a picks-and-shovels platform whose tools are indispensable to chip designers ranging from large fabless firms to systems companies moving into custom silicon. The current investor narrative is dominated by the transformative acquisition of Ansys, which has dramatically reshaped the company's revenue base and debt profile, while simultaneously fueling debate over organic growth quality versus acquisition-driven expansion. Recent headlines highlight a strong Q3 beat driven by AI-related demand for chip design software, yet the stock has faced pressure amid concerns that weak organic growth is being masked by the Ansys deal, creating a notable disconnect between analyst optimism and market price action.…
SNPS
Synopsys
$401.85
Related headlines
Investment Opinion: Should I buy SNPS Today?
The synthesized recommendation is Hold, with a bias toward accumulating on weakness. The core thesis is that Synopsys is a high-quality, mission-critical EDA monopoly trading at a reasonable forward valuation (21.97x forward PE) but facing significant near-term execution risk from the Ansys integration and margin compression. The analyst consensus is strong buy with an average target of $545.93, implying 41.8% upside, but the market is clearly demanding proof before re-rating the shares. The stock's 19.8% year-to-date decline and 34.8% underperformance versus SPY suggest that the bullish narrative is not yet resonating with investors.
Supporting evidence for a Hold includes: 1) Revenue growth of 41.87% YoY in Q2 2026, albeit inorganic, demonstrates the scale of the Ansys acquisition; 2) Free cash flow remains robust at $2.676 billion TTM, providing ample capacity to service debt; 3) The forward PE of 21.97x is below the trailing PE of 55.82x, implying a significant earnings recovery; 4) The price-to-book ratio of 2.57x is near multi-year lows, potentially signaling a value opportunity. However, these positives are offset by the 0.75% net margin, 4.70% ROE, and interest coverage of 1.77x, which highlight the financial strain from the acquisition.
The biggest risks that could invalidate the thesis are: 1) Continued organic growth deceleration, as evidenced by the sequential revenue decline from Q1 to Q2 2026; 2) Failure to restore net margins to the 20%+ level, which would make the forward PE of 22x look optimistic; 3) A breakdown below the 52-week low of $362.55, which could trigger further selling. The rating would upgrade to Buy if the company demonstrates two consecutive quarters of margin expansion and organic growth reacceleration, or if the stock drops below $350 (implying a forward PE below 20x). It would downgrade to Sell if organic growth turns negative or if interest coverage falls below 1.5x. Relative to its history and peers, SNPS appears fairly valued on a forward basis but overvalued on trailing metrics; the stock is a show-me story.
Sign up to view all
SNPS 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. Synopsys is a high-quality franchise with a wide moat in EDA, but the Ansys acquisition has introduced significant execution risk and financial leverage. The stock's 19.8% decline over the past year reflects these concerns, yet the forward PE of 22x suggests the market is pricing in a recovery. The key tension is whether the company can restore its historical 20%+ net margins and reaccelerate organic growth. If it does, the stock could easily reach the analyst average target of $545.93. If it doesn't, the stock could break below $362.55. I would upgrade to bullish if organic growth accelerates and margins expand for two consecutive quarters, and downgrade to bearish if organic growth turns negative or interest coverage falls below 1.5x.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Synopsys's 12-month outlook, with a consensus price target around $545.93 and implied upside of +35.9% versus the current price.
Average Target
$545.93
0 analysts
Implied Upside
+35.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$415 - $633
Analyst target range
Synopsys is covered by 26 analysts, with a consensus recommendation of "strong_buy" (recommendation mean of 1.48) and an average price target of $545.93, implying 41.8% upside from the current price of $384.97. The Buy/Hold/Sell distribution is heavily skewed toward Buy ratings, with recent actions including Piper Sandler's upgrade to Overweight from Neutral in June 2026, alongside Buy ratings from Rosenblatt, Citigroup, Needham, Stifel, and B of A Securities. This bullish consensus stands in stark contrast to the stock's 19.8% year-to-date decline, creating a significant disconnect that suggests either the market is overly pessimistic or analysts are slow to revise estimates downward.\n\nThe target price range spans from a low of $414.77 to a high of $633.00, a spread of $218.23 or 52.6% of the average target, indicating substantial disagreement about the company's trajectory. The high target of $633 assumes successful Ansys integration, restoration of 20%+ net margins, and a re-rating to premium multiples, while the low target of $414.77 (still 7.7% above current price) prices in continued margin pressure and sluggish organic growth. The wide spread signals high uncertainty, and with the stock trading below even the lowest analyst target, there is a clear divergence between analyst expectations and market pricing; if the company can deliver on even the low end of guidance, the risk-reward appears favorable, but the market is clearly demanding proof before re-rating the shares.
Bulls vs Bears: SNPS Investment Factors
The bear case currently has stronger evidence due to the stark disconnect between analyst optimism and market action: the stock is down 19.8% over the past year despite a strong buy consensus and 41.8% upside to the average target. The core tension is whether Synopsys can restore its historical 20%+ net margins and reaccelerate organic growth after the debt-funded Ansys acquisition, which has crushed GAAP profitability and left interest coverage dangerously thin. Bulls point to robust free cash flow of $2.68B and a forward PE of 22x that already discounts a recovery, while bears highlight the sequential revenue decline and 0.75% net margin as signs that the integration is not yet yielding synergies. The single most important factor is the trajectory of organic growth and margin recovery over the next 2-3 quarters; if the company can demonstrate that Ansys is accretive to margins and that organic growth is stable, the stock could re-rate sharply. Conversely, if organic growth stalls or integration costs persist, the stock could break below its 52-week low of $362.55.
Bullish
- Analyst consensus strong buy with 41.8% upside: 26 analysts rate SNPS a strong buy (mean 1.48) with an average target of $545.93, implying 41.8% upside from $384.97. Even the lowest target of $414.77 is 7.7% above the current price, suggesting the market is excessively pessimistic.
- Forward PE of 22x signals earnings recovery: The forward PE of 21.97x is less than half the trailing PE of 55.82x, implying the market expects EPS to more than double as Ansys synergies materialize and interest expenses normalize. Estimated EPS of $25.46 supports this trajectory.
- Free cash flow remains robust at $2.68B: Despite GAAP earnings pressure, trailing free cash flow is $2.676 billion, with $616.8 million generated in Q2 2026 alone. This cash generation provides ample capacity to service debt and fund integration.
- AI-driven demand fuels Q3 beat and guidance raise: Synopsys reported a strong Q3 beat and raised guidance, citing AI-driven demand for chip design software. This validates the secular growth thesis and suggests the company is a key enabler of AI infrastructure.
Bearish
- Organic growth deceleration masked by Ansys: Q2 2026 revenue grew 41.87% YoY to $2.276B, but this is entirely inorganic from the Ansys acquisition. Sequentially, revenue declined from $2.409B in Q1 2026, suggesting the acquisition bump is annualizing and organic growth is sluggish.
- Profitability collapsed on GAAP basis: Q2 2026 net income was just $17.1M (0.75% net margin) versus $345.3M (21.5% margin) a year ago. Operating margin fell to 10.4% from 23.5%, and ROE is a mere 4.70%, well below historical norms.
- Debt burden from Ansys acquisition: Debt-to-equity stands at 0.50, and interest expense spiked to $133.4M in Q2 2026, consuming over half of operating income of $236.3M. The cash flow-to-debt ratio of 0.062 indicates debt reduction will take years.
- Severe relative underperformance: SNPS is down 19.82% over the past year, underperforming SPY by 34.83 percentage points. The stock trades at just 71.3% of its 52-week range, reflecting persistent selling pressure and lack of buyer conviction.
SNPS Technical Analysis
Synopsys is mired in a sustained downtrend, with the stock down 19.82% over the past year and trading at just 71.3% of its 52-week range (current price of $384.97 versus a 52-week high of $539.48 and low of $362.55). This positioning near the lower quartile of the annual range signals persistent selling pressure and a lack of buyer conviction, though it also places the stock in territory where value-oriented investors may begin to take notice. The magnitude of the decline relative to the broader market is stark, with a relative strength of -34.83% versus SPY over the past year, indicating severe underperformance that reflects company-specific headwinds rather than broad market weakness.\n\nShort-term momentum remains negative but shows signs of stabilization, with the 1-month change at -4.05% and the 3-month change at -15.49%, both improving relative to the 6-month decline of -8.41%. The 1-month relative strength of -3.09% versus SPY suggests the stock is still lagging but by a narrower margin than the 3-month relative strength of -17.49%, hinting at a possible deceleration in selling pressure. The recent price action from a September low of $367.70 back to $384.97 represents a modest 4.7% bounce, though it remains well below the August spike to $464.89, which appears to have been a short-lived catalyst-driven rally that quickly faded.\n\nKey technical support is anchored at the 52-week low of $362.55, with the September 15 close of $367.70 serving as a recent test of that zone; a breakdown below this level would likely trigger accelerated selling and open the door to new lows. Resistance is established at the 52-week high of $539.48, but more immediately, the $440-$465 area (the August rally zone) represents the first meaningful hurdle for any recovery attempt. With a beta of 1.227, Synopsys is approximately 23% more volatile than the broader market, meaning position sizing should account for amplified drawdowns; the maximum drawdown of -41.2% over the period underscores the severity of risk in this name.
Beta
1.23
1.23x market volatility
Max Drawdown
-41.2%
Largest decline past year
52-Week Range
$363-$539
Price range past year
Annual Return
-18.9%
Cumulative gain past year
| Period | SNPS Return | S&P 500 |
|---|---|---|
| 1m | +1.0% | +1.0% |
| 3m | -12.9% | +5.4% |
| 6m | -2.0% | +17.8% |
| 1y | -18.9% | +16.5% |
| ytd | -16.4% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SNPS Fundamental Analysis
Synopsys' revenue trajectory has been transformed by the Ansys acquisition, with Q2 2026 (quarter ending April 30, 2026) revenue reaching $2.276 billion, representing 41.87% year-over-year growth from $1.604 billion in the prior-year quarter. However, this growth is heavily inorganic, and the sequential trend shows a decline from Q1 2026's $2.409 billion, suggesting that the acquisition bump may be annualizing. The revenue segment breakdown reveals a diversified base with License and Maintenance at $945.6 million, Technology Service at $784.1 million, and License at $546.3 million, but the company's organic growth engine appears to be decelerating, which is a critical concern for a stock that historically commanded premium multiples on consistent double-digit organic expansion.\n\nProfitability has deteriorated sharply on a GAAP basis, with Q2 2026 net income of just $17.1 million (net margin of 0.75%) compared to $345.3 million (21.5% margin) in the prior-year quarter, driven by a massive spike in interest expense to $133.4 million and other expenses of $155.3 million related to acquisition financing. Gross margin remains robust at 72.3% for the quarter, though this is down from 80.2% a year ago, reflecting the dilutive impact of Ansys's lower-margin business mix. The operating margin of 10.4% is a fraction of the 23.5% reported in Q2 2025, and the trailing twelve-month net margin of 18.9% masks the severity of the recent quarterly compression, which raises questions about the company's ability to restore historical profitability levels.\n\nThe balance sheet tells a story of aggressive leveraging, with debt-to-equity at 0.50 and a current ratio of 1.62, both reflecting the financing of the Ansys deal; interest coverage has fallen to dangerously low levels, with Q2 2026 interest expense of $133.4 million against operating income of $236.3 million. Free cash flow remains a bright spot at $2.676 billion on a trailing twelve-month basis, and the Q2 2026 free cash flow of $616.8 million demonstrates the company's ability to generate cash despite GAAP earnings pressure. However, ROE has collapsed to 4.70% and ROA to 1.35%, well below historical norms, and the cash flow-to-debt ratio of 0.062 signals that debt reduction will be a multi-year endeavor, limiting financial flexibility for share repurchases or strategic investments.
Quarterly Revenue
$2.3B
2026-04
Revenue YoY Growth
+41.9%
YoY Comparison
Gross Margin
72.3%
Latest Quarter
Free Cash Flow
$2.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SNPS Overvalued?
Given that Synopsys reported positive net income of $17.1 million in the most recent quarter, the PE ratio is the appropriate primary valuation metric, though the trailing PE of 55.82x is distorted by the depressed earnings base and is best interpreted alongside the forward PE of 21.97x. The massive gap between trailing and forward PE—a 60.6% decline—implies the market expects a substantial earnings recovery, likely driven by the realization of Ansys synergies, debt paydown, and normalization of interest expenses. This forward multiple suggests that if the company can execute on its integration plan, the stock is not egregiously expensive, but the risk lies in whether those expectations are achievable.\n\nOn a price-to-sales basis, Synopsys trades at 10.30x, which is elevated relative to the broader software infrastructure sector but reflects the company's mission-critical positioning and high switching costs. The EV/EBITDA of 33.63x and EV/Sales of 8.53x further underscore the premium valuation, though the PEG ratio of -1.24 is negative due to the earnings distortion and is not meaningful in this context. Compared to peers in the EDA and semiconductor IP space, Synopsys historically trades at a premium to the market, but the current multiples are difficult to justify without a clear path to restoring the 20%+ net margins the company enjoyed pre-acquisition.\n\nHistorical context is critical here: Synopsys' PE ratio has ranged from the low 40s to over 100x in recent years, and the current trailing PE of 55.82x sits in the middle of that band, while the PS ratio of 10.30x is well below the 30-58x range seen in 2025, reflecting the massive revenue base added by Ansys. The price-to-book ratio of 2.57x is near multi-year lows, down from over 11x in 2024, which could signal a value opportunity if the company can stabilize earnings. However, the market is clearly pricing in significant execution risk, and the stock will likely remain range-bound until there is evidence of organic growth reacceleration and margin recovery.
PE
55.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 37x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to the debt-funded Ansys acquisition. Debt-to-equity stands at 0.50, and Q2 2026 interest expense of $133.4 million consumed 56% of operating income ($236.3 million), leaving interest coverage at just 1.77x. The cash flow-to-debt ratio of 0.062 implies it would take over 16 years of current free cash flow to repay total debt, severely limiting financial flexibility. Additionally, GAAP net margin collapsed to 0.75% in Q2 2026 from 21.5% a year ago, and ROE is only 4.70%, well below the company's historical norms. Revenue concentration in the EDA and IP segments remains high, and the sequential revenue decline from Q1 to Q2 2026 suggests organic growth may be decelerating, which is a critical risk for a company that historically commanded premium multiples on consistent double-digit organic expansion.
Market and competitive risks stem from the stock's premium valuation and high volatility. The PS ratio of 10.30x and EV/EBITDA of 33.63x are elevated relative to peers, leaving little room for error. With a beta of 1.227, SNPS is 23% more volatile than the market, amplifying drawdowns during sector rotations. The stock has severely underperformed, with a 1-year relative strength of -34.83% versus SPY, and recent news highlights a disconnect between analyst optimism and market action, with concerns that weak organic growth is being masked by the Ansys deal. Regulatory risks are low, but competitive pressures in EDA and IP are intensifying, and the sale of the Processor IP Solutions business to GlobalFoundries may reduce diversification. Macro sensitivity is also a factor, as semiconductor demand is cyclical and any slowdown could pressure Synopsys' licensing revenue.
The worst-case scenario involves a breakdown below the 52-week low of $362.55, which would likely trigger accelerated selling and open the door to new lows. If organic growth stalls, margin recovery fails to materialize, and the company misses earnings expectations, the stock could retest its 52-week low and potentially fall further. The analyst low target of $414.77 is above the current price, but in a severe downturn, the stock could trade down to the 52-week low of $362.55, representing a 5.8% decline from the current price of $384.97. However, if the market prices in a recession or integration failure, the stock could fall to $300 or lower, implying a 22% downside. The maximum drawdown over the past period was -41.2%, underscoring the severity of risk in this name.
FAQ
The key risks for SNPS are: 1) Financial risk: The Ansys acquisition has left the company with debt-to-equity of 0.50 and interest coverage of just 1.77x, consuming over half of operating income. A decline in cash flow could strain the balance sheet. 2) Operational risk: GAAP net margin collapsed to 0.75% in Q2 2026, and ROE is only 4.70%. The company must restore margins to justify its valuation. 3) Market risk: The stock has a beta of 1.227, making it 23% more volatile than the market, and it has underperformed SPY by 34.8% over the past year. A breakdown below the 52-week low of $362.55 could trigger further selling. 4) Competitive risk: The EDA market is dominated by a few players, but any technological disruption or pricing pressure could impact Synopsys' margins. Ranked by severity, the financial and operational risks are most immediate, followed by market and competitive risks.
Our 12-month forecast for SNPS includes three scenarios. The bull case (25% probability) targets $545-$633, assuming successful Ansys integration, margin recovery to 20%+, and organic growth reacceleration. The base case (50% probability) targets $450-$550, assuming gradual integration progress and slow margin recovery. The bear case (25% probability) targets $362-$415, assuming integration challenges persist and organic growth stalls. The most likely scenario is the base case, with a target range of $450-$550, implying a potential upside of 17-43% from the current price of $384.97. The key assumption behind the base case is that Synopsys can stabilize organic growth at 8-10% and improve net margin to 12-15% by the end of 2027. However, if the company fails to execute, the bear case could materialize, with downside to the 52-week low of $362.55.
SNPS appears fairly valued on a forward basis but overvalued on trailing metrics. The trailing PE of 55.82x is distorted by depressed earnings, while the forward PE of 21.97x suggests the market expects a significant earnings recovery. The PS ratio of 10.30x and EV/EBITDA of 33.63x are elevated relative to peers, reflecting the company's premium positioning and high switching costs. Compared to its own history, the price-to-book ratio of 2.57x is near multi-year lows (down from over 11x in 2024), which could signal a value opportunity. However, the market is clearly pricing in execution risk, and the stock will likely remain range-bound until there is evidence of organic growth reacceleration and margin recovery. The forward PE implies the market expects EPS to more than double, which is a high bar.
SNPS presents a mixed risk/reward profile. On the positive side, the stock trades at a forward PE of 21.97x, well below its trailing PE of 55.82x, and analysts have a strong buy consensus with an average target of $545.93, implying 41.8% upside. The company generates robust free cash flow of $2.68 billion TTM and is a critical player in the AI-driven chip design ecosystem. However, the stock is down 19.8% over the past year, underperforming the S&P 500 by 34.8 percentage points, and GAAP net margin has collapsed to 0.75% due to the debt-funded Ansys acquisition. The biggest downside risk is a break below the 52-week low of $362.55, which could lead to further losses. For long-term investors with a high risk tolerance, SNPS could be a good buy on weakness, but near-term uncertainty remains high.
SNPS is more suitable for long-term investment than short-term trading. The company is in a transition period following the Ansys acquisition, and it will take several quarters to realize synergies and restore margins. The stock has a beta of 1.227, indicating above-average volatility, and it does not pay a dividend (payout ratio 0%), so returns depend entirely on capital appreciation. Short-term traders may find opportunities around earnings announcements, but the risk of drawdowns is high, as evidenced by the maximum drawdown of -41.2%. For long-term investors, the secular growth of the semiconductor industry and Synopsys' entrenched position in EDA provide a compelling narrative, but patience is required. A suggested minimum holding period is 2-3 years to allow for the full integration of Ansys and the realization of margin recovery. Investors should monitor quarterly earnings for signs of organic growth and margin improvement.